| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/16/2005 | CA2546452A1 Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens |
| 06/16/2005 | CA2546448A1 Biomarkers for the efficacy of somatostatin analogue treatment |
| 06/16/2005 | CA2546292A1 Enoxaparin for the treatment of cancer |
| 06/16/2005 | CA2546117A1 1h-imidazoquinoline derivatives as protein kinase inhibitors |
| 06/16/2005 | CA2546017A1 Use of notch pathway interfering agents for treatment of plasma cell disorders |
| 06/16/2005 | CA2541691A1 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases |
| 06/15/2005 | EP1541675A2 Hybrid cells obtainable from antigen presenting cells |
| 06/15/2005 | EP1541672A1 Composition for promoting the proliferation of lactobacillus casei subsp. casei |
| 06/15/2005 | EP1541585A1 Cxcr4 antagonist and use thereof |
| 06/15/2005 | EP1541584A1 A group of novel synthetic antibiotic peptides |
| 06/15/2005 | EP1541574A1 Triazaspiro 5.5 undecane derivatives and drugs comprisi ng the same as the active ingredient |
| 06/15/2005 | EP1541573A1 Novel crystals of triazaspiro 5.5 undecane derivative |
| 06/15/2005 | EP1541572A1 Thioether substituted imidazoquinolines |
| 06/15/2005 | EP1541571A1 Bicyclic unsaturated tertiary amine compound |
| 06/15/2005 | EP1541570A1 Novel physiologically active substance |
| 06/15/2005 | EP1541563A1 Ccr4 antagonist and medicinal use thereof |
| 06/15/2005 | EP1541560A1 Novel tetrahydroquinoline derivatives |
| 06/15/2005 | EP1541170A1 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| 06/15/2005 | EP1541150A1 Use of methylol transfer agents for treatment of mesothelioma |
| 06/15/2005 | EP1541149A1 Phosphodiesterase inhibitor |
| 06/15/2005 | EP1541139A1 Drug composition containing nf-kappa b inhibitor |
| 06/15/2005 | EP1541135A1 Hollow nanoparticle having modified cysteine residue and drug with the use thereof |
| 06/15/2005 | EP1541125A1 Spreadable compositions for topical use, a process of making same and uses thereof |
| 06/15/2005 | EP1540012A2 Polymorphisms for predicting disease and treatment outcome |
| 06/15/2005 | EP1539990A2 PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE |
| 06/15/2005 | EP1539971A1 Her-2/neu dna vaccine having anti-cancer activity |
| 06/15/2005 | EP1539957A1 Novel diagnostic and therapeutic methods and reagents therefor |
| 06/15/2005 | EP1539956A2 GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF |
| 06/15/2005 | EP1539942A2 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| 06/15/2005 | EP1539933A2 Methods of organ regeneration |
| 06/15/2005 | EP1539931A1 Differentiation modulating agents and uses therefor |
| 06/15/2005 | EP1539818A2 Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells |
| 06/15/2005 | EP1539813A2 Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer |
| 06/15/2005 | EP1539805A2 Nucleic acids and corresponsing proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer |
| 06/15/2005 | EP1539804A2 Synthesis and characterization of novel systems for guidance and vectorization of molecules of therapeutic interest towards target cells |
| 06/15/2005 | EP1539793A2 Humanized anti-lymphotoyin beta receptor antibodies |
| 06/15/2005 | EP1539783A1 Inhibitors of nucleoside phosphorylases and nucleosidases |
| 06/15/2005 | EP1539769A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 06/15/2005 | EP1539768A2 A new process for the preparation of epothilone derivatives, new epothilone derivatives as well as new intermediate products for the process and the methods of preparing same |
| 06/15/2005 | EP1539763A1 Azaindole kinase inhibitors |
| 06/15/2005 | EP1539760A2 Azapurine derivatives |
| 06/15/2005 | EP1539756A2 Imidazopyridines as cyclin dependent kinase inhibitors |
| 06/15/2005 | EP1539754A2 Benzimidazole quinolinones and uses thereof |
| 06/15/2005 | EP1539750A1 Pyrazolopyridines as cyclin dependent kinase inhibitors |
| 06/15/2005 | EP1539741A1 2-thio-substituted imidazole derivatives and their use in pharmaceutics |
| 06/15/2005 | EP1539739A1 Piperidinyl compounds that selectively bind integrins |
| 06/15/2005 | EP1539732A1 Novel compounds |
| 06/15/2005 | EP1539730A1 Novel compunds, pharmaceutical compositions containing same, and methods of use for same |
| 06/15/2005 | EP1539729A2 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 06/15/2005 | EP1539727A2 Compounds, compositions, and methods |
| 06/15/2005 | EP1539725A1 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors |
| 06/15/2005 | EP1539701A1 Caspase inhibitors and uses thereof |
| 06/15/2005 | EP1539699A1 4- 7'-halo-2-quino (xa-) linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents |
| 06/15/2005 | EP1539696A2 Process for preparing quinolin antibiotic intermediates |
| 06/15/2005 | EP1539693A1 Cannabinoid receptor agonists |
| 06/15/2005 | EP1539686A1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
| 06/15/2005 | EP1539683A2 Phenol derivatives and their use as rotamase inhibitors |
| 06/15/2005 | EP1539679A2 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| 06/15/2005 | EP1539678A1 3,4-di-substituted cyclobutene-1, 2-diones as cxc-chemokine receptor ligands |
| 06/15/2005 | EP1539674A1 Amino-propanol derivatives |
| 06/15/2005 | EP1539662A1 Cannabinoid receptor ligands |
| 06/15/2005 | EP1539250A1 Radioactively labelled amino acid analogues, their preparation and use |
| 06/15/2005 | EP1539245A2 Methods and materials for treating human papillomavirus infections |
| 06/15/2005 | EP1539237A2 Humanized antibodies against human 4-1bb |
| 06/15/2005 | EP1539216A2 Labelled somatostatin analogs backbone cyclized through metal complexation |
| 06/15/2005 | EP1539211A2 Method of up-regulating tumor antigen expression using thymalfasin |
| 06/15/2005 | EP1539208A2 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 06/15/2005 | EP1539207A1 Treatment of cell proliferative disorders with chlorotoxin |
| 06/15/2005 | EP1539204A1 Plant extracts for treatment of angiogenesis and metastasis |
| 06/15/2005 | EP1539191A1 Glycoalkaloid compositions and various uses thereof |
| 06/15/2005 | EP1539186A1 Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor |
| 06/15/2005 | EP1539180A2 Compounds, compositions, and methods |
| 06/15/2005 | EP1539179A2 Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof |
| 06/15/2005 | EP1539150A1 Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof |
| 06/15/2005 | EP1539131A2 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
| 06/15/2005 | EP1539125A1 A composition comprising phytospingosine derivatives for apoptosis induction |
| 06/15/2005 | EP1539123A1 Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer |
| 06/15/2005 | EP1539108A1 Vesicle-encapsulated corticosteroids for the treatment of cancer |
| 06/15/2005 | EP1539107A2 Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| 06/15/2005 | EP1539106A2 Buccal polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 06/15/2005 | EP1539102A2 Pharmaceutically active lipid based formulation of sn38 |
| 06/15/2005 | EP1538913A2 Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| 06/15/2005 | EP1538900A2 Cancer vaccines containing epitopes of oncofetal antigen |
| 06/15/2005 | EP1538888A2 Upper hitch link |
| 06/15/2005 | EP1427842A4 Mid 9002, a human sulfatase family member and uses therefor |
| 06/15/2005 | EP1383924A4 Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof |
| 06/15/2005 | EP1373240B1 Retinoid x receptor modulators |
| 06/15/2005 | EP1372669B1 Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
| 06/15/2005 | EP1359816B1 Combination of probiotics |
| 06/15/2005 | EP1325007B1 Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction |
| 06/15/2005 | EP1311259B1 Pharmaceutical composition comprising an ester of 5-aminolevulinic acid as photochemotherapeutic agent and a mucoadhesive agent |
| 06/15/2005 | EP1309625B1 Therapeutic compounds for ovarian cancer |
| 06/15/2005 | EP1289916A4 Purification of xanthophylls from marigold extracts that contain high levels of chlorophylls |
| 06/15/2005 | EP1276496B1 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 06/15/2005 | EP1256576B1 Fused imidazolium derivatives |
| 06/15/2005 | EP1248836B1 Method for preparing vaccines by using hybrid cells |
| 06/15/2005 | EP1248785B1 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same |
| 06/15/2005 | EP1248610B1 Use of at least a fatty ester for preparing a composition for the therapeutic and/or cosmetic treatment of prostatic hypertrophy, prostatic adenocarcinoma, acne, hyperseborrhea, alopecia and hirsutism |
| 06/15/2005 | EP1198255A4 Identification of compounds that modify transcriptional responses to hypoxia |
| 06/15/2005 | EP1165070B1 Thiadiazolyl urea or thiourea derivatives for antiviral treatment |